PharmaDrug Inc.

77 King Street West
Suite 2905
Toronto, ON
Canada M5K 1H1

Recent News

  • PharmaDrug Announces Positive Findings for the Combination of Cepharanthine and Frontline Chemotherapy for IND-Enabling Esophageal Cancer Study

    Results show that oral cepharanthine plus paclitaxel (combination therapy) significantly reduced tumor volume and increased tumor growth inhibition at day 28, the final day of dosing compared to paclitaxel alone (p=0.0049)Dose range finding demonstrates that oral cepharanthine-alone was well tolerated in the current in vivo study Toronto, Ontario--(Newsfile Corp. - June 16, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines...

    2022-06-16 7:00 AM EDT
  • PharmaDrug Announces Execution Of an Agreement to Sell Its German Cannabis Asset to Khiron

    Toronto, Ontario--(Newsfile Corp. - May 31, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), is pleased to announce that it has entered into an agreement on May 31, 2022 with Khiron Life Sciences Corp. (TSXV: KHRN) ("Khiron") to sell all of the outstanding securities of Pharmadrug Production GmbH, ("Pharmadrug GMBH") the Company's wholly-owned German subsidiary, a medical cannabis distributor, with a Schedule I European Union narcotics license and German EuGMP certification allowing for the importation and...

    2022-05-31 8:46 AM EDT
  • PharmaDrug Announces Closing of the First Tranche of Non-Brokered Private Placement

    Toronto, Ontario--(Newsfile Corp. - May 27, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce the closing of the first tranche (the "First Tranche") of a non-brokered private placement (the "Offering") of units in the capital of the Company (the "Units"). Pursuant to the closing of the First Tranche,...

    2022-05-27 4:15 PM EDT
  • Pharmadrug Advances Opthalmology Program with Final Selection of Lead DMT-Analogue to Provide Sustained Control of Elevated Intraocular Pressure for Glaucoma

    Selection of lead candidate from initial short-list of 6 DMT-analoguesLead candidate displays superior potency in two in vitro bioassays on two relevant human cell types In vitro safety and biocompatibility testing using drug-loaded medical device demonstrates tolerability at doses anticipated to be within therapeutic range Results to be leveraged by filing of Provisional Patent detailing a novel approach to treating primary open angle glaucomaInitiates plans for second stage of R&D with Terasaki Institute for Biomedical InnovationToronto, Ontario--(Newsfile Corp. -...

    2022-05-03 8:00 AM EDT
  • PharmaDrug Advances Oncology Program with Filing of Provisional Patent Following Positive Findings for the Combination of PD-001 and Frontline Chemotherapy in Prostate Cancer Study

    Provisional patent filed (April 14, 2022) to support use of PD-001 plus cabazitaxel for primary, metastatic and chemotherapy-resistant prostate cancerFinal study results show that oral cepharanthine (PD-001) plus cabazitaxel combination therapy significantly reduced tumor volume and increased tumor growth inhibitionDose range finding demonstrates that oral cepharanthine-alone was well tolerated Addition of PD-001 to cabazitaxel dosing regimen did not increase toxicityToronto, Ontario--(Newsfile Corp. - April 19, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("

    2022-04-19 7:30 AM EDT
  • PharmaDrug Advances DMT-Analogue Program for Glaucoma with Production of Medical Device Designed to Provide Sustained Control of Elevated Intraocular Pressure

    Prototype medical device engineered to deliver sustained, sub-psychedelic quantities of candidate DMT-analogues In vitro, time dependent drug elution profile evaluated for three candidate moleculesBiocompatibility of drug-loaded medical device demonstrates cell-based safety at doses anticipated to be within therapeutic range Current results provide Company with refined focus for two candidate moleculesToronto, Ontario--(Newsfile Corp. - April 7, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances...

    2022-04-07 7:30 AM EDT
  • Pharmadrug Advances PD-001, Its Patented, Improved Version of Cepharanthine for Oncology and Infectious Disease

    Committed to the 'pipeline-in-a-pill' approach with PD-001 for certain cancers and COVID-19Advances cGMP manufacturing of clinical drug supply with Southwest Research InstituteReceives final positive data for recently conducted prostate cancer model and evaluates opportunities to broaden claim set for PD-001 in the treatment of cancerInitiates IND-enabling efficacy study of PD-001 to treat esophageal cancerEvaluates opportunities to deepen and broaden testing of PD-001 as a broad-spectrum oral antiviral Toronto, Ontario--(Newsfile Corp. - April 1, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB:...

    2022-04-01 8:23 AM EDT
  • PharmaDrug Announces Interim Positive Findings for the Combination of Cepharanthine and Frontline Chemotherapy for IND-Enabling Prostate Cancer Study

    Interim results show that oral cepharanthine plus cabazitaxel (combination therapy) significantly reduced tumor volume and increased tumor growth inhibition at day 21, the final day of dosingDose range findings demonstrate that oral cepharanthine-alone was well tolerated in the current in vivo study Results for oral cepharanthine plus cabazitaxel will be used to support PharmaDrug's recently submitted provisional patent application which details a novel treatment combination for primary, metastatic and chemotherapy-resistant prostate cancerToronto, Ontario--(Newsfile Corp. - March 9, 2022) - PharmaDrug...

    2022-03-09 7:30 AM EST